← Retour au Screener

Sector: Santé
Open in Terminal → INMDLive chart · Key metrics · News · Smart money

InMode

INMD Small Cap

Healthcare · Medical Devices

Mis à jour: Jun 18, 2026, 22:21 UTC

11,69 €
+0.3% aujourd'hui
52W: 11,10 € – 14,61 €
52W Low: 11,10 € Position: 16.9% 52W High: 14,61 €

Price Chart

Indicateurs clés

P/E Ratio
9.93x
Cours/Bénéfice
Forward P/E
9.22x
P/E prévisionnel
P/S Ratio
2.17x
Cours/Ventes
EV/EBITDA
4.01x
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
711 M €
Capitalisation boursière
Croissance du CA
5.3%
Croissance du CA sur un an
Marge bénéficiaire
23.27%
Marge nette
ROE
13.62%
Rentabilité des capitaux propres
Beta
1.93
Sensibilité au marché
Positions vendeuses
5.05%
% du flottant vendu à découvert
Volume moyen
838,088
Volume quotidien moyen

Valuation Analysis

Signal
Undervalued
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Conserver
3 analysts
Avg. Price Target
12,51 €
+6.97% upside
Target Range
12,22 € – 13,09 €

About the Company

Sector: Healthcare Industry: Medical Devices Country: Israel Employees: 660 Exchange: NMS

InMode en bref

InMode (INMD) is currently trading at 11,69 € with a market capitalization of 711 M €. The trailing P/E ratio stands at 9.93x, with a forward P/E of 9.22x. The 52-week range spans from 11,10 € to 14,61 €; the current price is 20% below the yearly high. Year-over-year revenue growth stands at +5.3%. The net profit margin stands at 23.27%.

💰 Dividende

InMode currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

3 analystes évaluent InMode (INMD) au consensus : Conserver. L'objectif de cours moyen est de 12,51 €, soit un potentiel de +6.97% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 12,22 € à 13,09 €.

InMode : la thèse d'investissement en détail

InMode (INMD) operates in the Healthcare — specifically Medical Devices — and is headquartered in Israel. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 77.84%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 23.27%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

With a beta near 1.93, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.

Valorisation en contexte

With a PEG ratio of 0.83, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 4.01x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

  • The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.

Thèse d'investissement : forces et faiblesses

Points forts
  • Rentable avec une marge nette de 23.27%
  • Marge brute élevée de 77.84% — signe d'un pouvoir de fixation des prix
  • Actuellement jugée sous-évaluée
  • Bilan solide avec faible endettement (D/E 0.73)
  • Free cash flow positif
Points faibles

Aucun signal d'alerte significatif dans les indicateurs actuels.

Aperçu technique

MM 50 jours
12,16 €
-3.8% vs. cours
MM 200 jours
12,55 €
-6.82% vs. cours
Sous le plus haut 52s
−20%
14,61 €
Au-dessus du plus bas 52s
+5.3%
11,10 €

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

Risque de marché (Bêta)
1.93 · Élevé
Évolue plus que le marché global
Positions vendeuses
5.05% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
0.73 · Faible
Dette totale / capitaux propres

The data points to above-average price swings, elevated short interest (5.05%).

Trading Data

50-Day MA: 12,16 €
200-Day MA: 12,55 €
Volume: 517,747
Avg. Volume: 838,088
Short Ratio: 2.78
P/B Ratio: 1.24x
Debt/Equity: 0.73x
Free Cash Flow: 38 M €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy InMode?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut